Feeds:
Posts
Comments

Archive for August 2nd, 2021

I am following up on the Sales Letter below for the SALE of Assets and Intellectual Property of Serene Medical, Inc.  

As previously indicated, Serene, based in Brisbane, Australia, is a radio frequency (RF) medical device/technology company that employs its patented platform transdermal delivery technology. The offering consists of Nuebelle Therapy for aesthetic surgeons and for migraine specialists.

FYI, please click on this link https://doi.org/10.1093/asj/sjz172 to review a paper by Dr. James Newman on “Multicenter Efficacy Trial of Percutaneous Radiofrequency System for the Reduction of Glabellar Lines”.  This was published in the Aesthetic Surgery Journal in the Oxford Academic.

Serene has raised approximately $35 million to date, with an initial $5 million focused on the clinical trials of the RF Technology. The majority shareholders are venture capital firms M.H. Carnegie & Co and January Capital. 

As bids are due on Friday, August 20, per the Bidding Process below, I am following up after leaving a voice mail to qualify your interest.

I am aware of busy schedules during these times and would appreciate the courtesy of a call/email to qualify interest.

Thank you in advance for taking the time to review and qualify.

 Update to “The Bidding Process, Procedures for the SALE of the Assets and Intellectual Property of Serene Medical, Inc.”

Gerbsman Partners (www.gerbsmanpartners.com) has been retained by Serene Medical Pty Ltd (www.serenemedical.com) to solicit interest for the acquisition of all, or substantially all, the assets of Serene Medical and its subsidiaries, further referred to as “Serene”, “Serene Medical” or “The Company”.  Further to Gerbsman Partners sales letter of July19, 2021 regarding the SALE of the Assets of Serene Medical, Inc., Please see attached Exhibit A, NDA, Exhibit B, IP Portfolio, Exhibit C, Inventory, detail Sales Letter with Appendix, Serene Medical power point and Table of Contents for access to the on line Due Diligence room (subject to an NDA). 

Based in Brisbane, Australia, Serene is a radio frequency (RF) medical device/technology company that employs its patented platform transdermal delivery technology. The offering consists of Nuebelle Therapy for aesthetic surgeons and for migraine specialists. 

Serene has raised approximately $35 million to date, with an initial $5 million focused on the clinical trials of the RF Technology. The majority shareholders are venture capital firms M.H. Carnegie & Co and January Capital. 

The Serene assets include IP/patents (16 registered patents), clinical trial results, inventory and fixed assets.

IMPORTANT LEGAL NOTICE: 

Interested and qualified parties will be expected to sign a non-disclosure agreement (attached hereto as Exhibit A) before they will be given access to key members of the management and intellectual capital teams and the due diligence “war room” documentation (the “Due Diligence Materials”). Each interested party, upon accessing the Due Diligence Materials granted to it, shall be deemed to acknowledge and agree: (i) that it is bound by the bidding procedures described herein; (ii) that it has an opportunity to inspect and examine the Serene Medical assets, to review all pertinent documents and information with respect thereto and raise such enquiries as it considers necessary; (iii) that it is not relying upon any written or oral statements, representations, or warranties of Serene, Gerbsman Partners, or their respective staff, agents, or attorneys; and (iv) all documents and reports provided to it have been provided solely for the convenience of the interested party, and Serene, Gerbsman Partners (and their respective, staff, agents, or attorneys) do not make any representations as to the accuracy or completeness of the same.  

Following an initial round of due diligence, interested parties will be invited to participate with a sealed bid, for the acquisition of the Serene Medical assets. Sealed bids must be submitted so that the bid is actually received by Gerbsman Partners no later than Friday, August 20 2021, 3:00pm Pacific Standard Time (the “Bid Deadline”).  Please also email steve@gerbsmanpartners.com with any bid.

Bids should identify those assets being tendered for in a specific and identifiable way. The attached Serene Medical Fixed Asset Schedule may not be complete. 

Any person or other entity making a bid must be prepared to provide independent confirmation that they possess the financial resources to complete the purchase. All bids must be accompanied by a refundable deposit via check in the amount of US$100,000 (payable to Serene Medical). The winning bidder will be notified within 3 business days after the Bid Deadline. Non-successful bidders will have their deposit returned to them. Until a binding sale agreement is entered into, Serene Medical reserves the right to, in its sole discretion, accept or reject any bid without giving reasons for its decision, withdraw any assets from sale or choose not to proceed with the sale.

Serene Medical will require the successful bidder to close within 7 business days (or such later date as agreed to or notified by Serene Medical at its discretion).  Any or all of the assets of Serene Medical will be sold on an “as is, where is” basis, with no representation or warranties whatsoever.

All sales and transfer taxes, stamp duty, goods and services taxes (GST) or similar taxes, if any, relating to the sale of the Serene Medical assets shall be payable by the successful bidder.

For additional information, please see below and/or contact: 

The Bidding Process for Interested Buyers

Interested and qualified parties will be expected to sign a non-disclosure agreement (attached hereto as Exhibit A) before they will be given access to key members of the management and intellectual capital teams and the due diligence “war room” documentation (the “Due Diligence Materials”). Each interested party, upon accessing the Due Diligence Materials granted to it, shall be deemed to acknowledge and agree: (i) that it is bound by the bidding procedures described herein; (ii) that it has an opportunity to inspect and examine the Serene Medical assets, to review all pertinent documents and information with respect thereto and raise such enquiries as it considers necessary; (iii) that it is not relying upon any written or oral statements, representations, or warranties of Serene, Gerbsman Partners, or their respective staff, agents, or attorneys; and (iv) all documents and reports provided to it have been provided solely for the convenience of the interested party, and Serene, Gerbsman Partners (and their respective, staff, agents, or attorneys) do not make any representations as to the accuracy or completeness of the same.  

Following an initial round of due diligence, interested parties will be invited to participate with a sealed bid, for the acquisition of the Serene Medical assets. Sealed bids must be submitted so that the bid is actually received by Gerbsman Partners no later than Friday, August 20 2021, 3:00pm Pacific Standard Time (the “Bid Deadline”).  Please also email steve@gerbsmanpartners.com with any bid.

Bids should identify those assets being tendered for in a specific and identifiable way. The attached Serene Medical Fixed Asset Schedule may not be complete. 

Any person or other entity making a bid must be prepared to provide independent confirmation that they possess the financial resources to complete the purchase. All bids must be accompanied by a refundable deposit via check in the amount of US$100,000 (payable to Serene Medical). The winning bidder will be notified within 3 business days after the Bid Deadline. Non-successful bidders will have their deposit returned to them. Until a binding sale agreement is entered into, Serene Medical reserves the right to, in its sole discretion, accept or reject any bid without giving reasons for its decision, withdraw any assets from sale or choose not to proceed with the sale.

Serene Medical will require the successful bidder to close within 7 business days (or such later date as agreed to or notified by Serene Medical at its discretion).  Any or all of the assets of Serene Medical will be sold on an “as is, where is” basis, with no representation or warranties whatsoever.

All sales and transfer taxes, stamp duty, goods and services taxes (GST) or similar taxes, if any, relating to the sale of the Serene Medical assets shall be payable by the successful bidder.

For additional information, please see below and/or contact: 

Steven R. Gerbsman                                                                             

steve@gerbsmanpartners.com

Kenneth Hardesty

ken@gerbsmanpartners.com

Read Full Post »